Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 14/20 | 0.61 |
| ▸ | KDR | P35968 | 14/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 12/20 | 0.61 |
| ▸ | EGFR | P00533 | 6/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.55 |
| ▸ | FLT1 | P17948 | 3/20 | 0.55 |
| ▸ | GAK | O14976 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30638095 | 1.00 | EPHA2 (0.61) | EPHA2KDREPHB4EGFRERBB2 | |
| SCHEMBL29087923 | 0.92 | EPHA2 (0.56) | EPHA2KDREPHB4EGFRERBB2 | |
| SCHEMBL30638106 | 0.92 | EPHA2 (0.56) | EPHA2KDREPHB4EGFRERBB2 | |
| SCHEMBL5568278 | 0.91 | EGFR (0.69) | EPHA2KDREPHB4EGFRERBB2 | |
| SCHEMBL30638107 | 0.91 | EGFR (0.69) | EPHA2KDREPHB4EGFRERBB2 | |
| SCHEMBL5568035 | 0.87 | EGFR (0.58) | EPHA2KDREPHB4EGFRERBB2 | |
| SCHEMBL5564700 | 0.87 | EGFR (0.69) | EPHA2KDREPHB4EGFRERBB2 | |
| SCHEMBL5569617 | 0.86 | EGFR (0.67) | EPHA2KDREPHB4EGFRERBB2 | |
| SCHEMBL5565280 | 0.84 | EGFR (0.66) | EPHA2KDREPHB4EGFRERBB2 | |
| SCHEMBL30638099 | 0.84 | EGFR (0.64) | EPHA2KDREPHB4EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116655599-A | Synthesis and application of EGFR allosteric inhibitors | 江南大学 | 2023-08-29 | — | — | CN | disclosed |
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-08 | — | — | US | disclosed |
| EP-1664028-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026151-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032508-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ABL1, ERBB2, LCK | EPHA2 699/4885KDR 49/4885EPHB4 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.